Exebacase
PreclinicalProtein / enzyme
Exebacase is one of 12 small molecule programs targeting COVID-19. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
311 competitors in COVID-19
#DrugCompanyPhaseTrials
1Other Tkis
BayerPreclinical
Serology
UUniversity Hospital Center of Martinique
Preclinical
Pfizer-Biontech COVID-19 MRNA Vaccine
PfizerPreclinical
Administration of Almitrine
CCentre Hospitalier Universitaire de Nice
Preclinical
Tpa
UUniversity of Florida
Preclinical
Thrombolytic
FFaculty Hospital Kralovske Vinohrady
Preclinical
SARS-Cov-2 Bivalent MRNA Vaccine
AAIM Vaccine Co., Ltd.
Preclinical
Serological Test
CCentre Hospitalier de Cornouaille
Preclinical
Exebacase
CContraFect
Preclinical
Dornase Alfa Inhalant Product
UUniversity Hospital, Strasbourg, France
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Exebacase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Preclinical[1]
- Company
- CContraFect